It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...